Oklo Inc. (OKLO) vs RECURSION PHARMACEUTICALS, INC. (RXRX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | OKLO | RXRX |
|---|---|---|
| Sector | Utilities | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | — | $74.68M |
| Revenue growth (YoY) | — | ▲ 26.9% |
| Net income | -$105.66M | -$644.76M |
| Gross margin | — | — |
| Diluted EPS | $-0.72 | $-1.44 |
| Insider net (6 mo) | +1.9M sh · 68 sells · 0 buys | +53.8K sh · 17 sells · 0 buys |
| Institutional owners | 42 | 41 |
| Institutional value held | $3.64B | $1.02B |
| Next earnings (est.) | — | Around Nov 4, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About Oklo Inc. (OKLO)
Oklo Inc., founded in 2013, is developing next-generation fast fission nuclear power plants called "Aurora powerhouses" designed to produce 15-75 megawatts electric (with potential expansion to 100 MWe and higher) using fresh, recycled, or down-blended… Read more →
About RECURSION PHARMACEUTICALS, INC. (RXRX)
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives, operating with a limited operating history and no products yet approved for commercial sale. Read more →
Source: SEC EDGAR.